507 related articles for article (PubMed ID: 26981243)
1. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.
Koelzer VH; Rothschild SI; Zihler D; Wicki A; Willi B; Willi N; Voegeli M; Cathomas G; Zippelius A; Mertz KD
J Immunother Cancer; 2016; 4():13. PubMed ID: 26981243
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Villadolid J; Amin A
Transl Lung Cancer Res; 2015 Oct; 4(5):560-75. PubMed ID: 26629425
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
[TBL] [Abstract][Full Text] [Related]
5. Toxicity management of immunotherapy for patients with metastatic melanoma.
Linardou H; Gogas H
Ann Transl Med; 2016 Jul; 4(14):272. PubMed ID: 27563659
[TBL] [Abstract][Full Text] [Related]
6. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
[TBL] [Abstract][Full Text] [Related]
8. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Läubli H; Balmelli C; Bossard M; Pfister O; Glatz K; Zippelius A
J Immunother Cancer; 2015; 3():11. PubMed ID: 25901283
[TBL] [Abstract][Full Text] [Related]
9. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
10. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
[TBL] [Abstract][Full Text] [Related]
12. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
13. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.
Weber JS
Am Soc Clin Oncol Educ Book; 2012; ():174-7. PubMed ID: 24451730
[TBL] [Abstract][Full Text] [Related]
14. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
[TBL] [Abstract][Full Text] [Related]
15. Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma.
Zibelman M; Olszanski AJ
J Natl Compr Canc Netw; 2014 Oct; 12(12 Suppl 2):S1-S5. PubMed ID: 31094496
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
17. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
18. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors.
Kamińska-Winciorek G; Cybulska-Stopa B; Lugowska I; Ziobro M; Rutkowski P
Postepy Dermatol Alergol; 2019 Aug; 36(4):382-391. PubMed ID: 31616210
[TBL] [Abstract][Full Text] [Related]
19. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
[TBL] [Abstract][Full Text] [Related]
20. A Review of Immune-Mediated Adverse Events in Melanoma.
Kennedy LB; Salama AKS
Oncol Ther; 2019 Dec; 7(2):101-120. PubMed ID: 32699983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]